Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Barton, J. C.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

DIAGNOSIS AND MANAGEMENT

Management of Hemochromatosis

right arrow James C. Barton, MD; Sharon M. McDonnell, MD, MPH; Paul C. Adams, MD; Pierre Brissot, MD; Lawrie W. Powell, MD; Corwin Q. Edwards, MD; James D. Cook, MD; Kris V. Kowdley, MD, The Hemochromatosis Management Working Group*

1 December 1998 | Volume 129 Issue 11 Part 2 | Pages 932-939

The complications of iron overload in hemochromatosis can be avoided by early diagnosis and appropriate management.Therapeutic phlebotomy is used to remove excess iron and maintain low normal body iron stores, and it should be initiated in men with serum ferritin levels of 300 µg/L or more and in women with serum ferritin levels of 200 µg/L or more, regardless of the presence or absence of symptoms. Typically, therapeutic phlebotomy consists of 1) removal of 1 unit [450 to 500 mL] of blood weekly until the serum ferritin level is 10 to 20 µg/L and 2) maintenance of the serum ferritin level at 50 µg/L or less thereafter by periodic removal of blood. Hyperferritinemia attributable to iron overload is resolved by therapeutic phlebotomy. When applied before iron overload becomes severe, this treatment also prevents complications of iron overload, including hepatic cirrhosis, primary liver cancer, diabetes mellitus, hypogonadotrophic hypogonadism, joint disease, and cardiomyopathy. In patients with established iron overload disease, weakness, fatigue, increased hepatic enzyme concentrations, right upper quadrant pain, and hyperpigmentation are often substantially alleviated by therapeutic phlebotomy. Patients with liver disease, joint disease, diabetes mellitus and other endocrinopathic abnormalities, and cardiac abnormalities often require additional, specific management. Dietary management of hemochromatosis includes avoidance of medicinal iron, mineral supplements, excess vitamin C, and uncooked sea-foods. This can reduce the rate of iron reaccumulation; reduce retention of nonferrous metals; and help reduce complications of liver disease, diabetes mellitus, and Vibrio infection. This comprehensive approach to the management of hemochromatosis can decrease the frequency and severity of iron overload, improve quality of life, and increase longevity.

Author and Article Information
space

From Southern Iron Overload Disorders Center, Birmingham, Alabama; Centers for Disease Control and Prevention, Atlanta, Georgia; London Health Sciences Centre, London, Ontario, Canada; Hopital Universitaire Pontchaillou, Rennes, France; University of Queensland, Brisbane, Australia; University of Utah College of Medicine and LDS Hospital, Salt Lake City, Utah; University of Kansas Medical Center, Kansas City, Kansas; and University of Washington, Seattle, Washington.
*The Hemochromatosis Management Working Group also includes Linda Cocchiarella, MD, MSc; James S. Dooley, MD; Vincent Fellitti, MD; David Brandhagen, MD; Victor Herbert, MD, JD; and Margit A. Krikker, MD.
Acknowledgments: The authors thank Dr. Anne C. Looker of the National Center for Health Statistics for reviews of data on age, sex, and serum iron variables from the National Health and Nutrition Examination Survey.
Grant Support: In part by Maternal and Child Health Branch, Division of Nutrition, Centers for Disease Control and Prevention (Atlanta, Georgia) and Southern Iron Disorders Center (Birmingham, Alabama).
Requests for Reprints: James C. Barton, MD, Southern Iron Disorders Center, Suite G-105, 2022 Brookwood Medical Center Drive, Birmingham, AL 35209; e-mail, ironmd{at}mem.po.com.
Current Author Addresses: Dr. Barton: Southern Iron Overload Disorders Center, suite G-105, 2022 Brookwood Medical Center Drive, Birmingham, AL 35209.
Dr. McDonnell: Centers for Disease Control and Prevention, Division of Nutrition and Physical Activity, 4770 Buford Highway Mailstop K-25, Atlanta, GA 30341-3724.
Dr. Adams: Department of Medicine, London Health Sciences Centre, University Campus, 339 Windermere Road, PO Box 5339, London, Ontario N6A 5A5, Canada.
Dr. Brissot: Clinique des Maladies du Foie, Unite INSERM U49, Hopital Universitaire Pontchaillou, 35033 Rennes, France.
Dr. Powell: The University of Queensland, Queensland Institute of Medical Research, The Bancroft Center, 300 Herston Road, Brisbane 4029 QLD, Australia.
Dr. Edwards: Department of Medicine, University of Utah College of Medicine and LDS Hospital, Outpatient Clinic, 325 8th Avenue, Salt Lake City, UT 84143.
Dr. Cook: Division of Hematology, University of Kansas Medical Center, 39th and Rainbow, Kansas City, KS 66103.
Dr. Kowdley: Division of Gastroenterology and Hepatology, RG-24, University of Washington, Seattle, WA 98195.
Note: This article is one of a series of articles comprising an Annals of Internal Medicine supplement entitled "Iron Overload, Public Health, and Genetics." To view a complete list of the articles included in this supplement, please view its Table of Contents.


Related articles in Annals:

Letters
Hemochromatosis and Vitamin C
Victor Herbert
Annals 1999 131: 475-476. [Full Text]  

Letters
Hemochromatosis and Vitamin C
James C. Barton, Paul C. Adams, AND Lawrie W. Powell
Annals 1999 131: 476. [Full Text]  



This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
M. Reynolds, L. Stoddard, I. Bespalov, and A. Zhitkovich
Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair
Nucleic Acids Res., January 28, 2007; 35(2): 465 - 476.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. T. Chung, J. Misdraji, and D. V. Sahani
Case 33-2006 -- A 43-Year-Old Man with Diabetes, Hypogonadism, Cirrhosis, Arthralgias, and Fatigue
N. Engl. J. Med., October 26, 2006; 355(17): 1812 - 1819.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
P.-A. Krayenbuehl, F. E. Maly, M. Hersberger, P. Wiesli, A. Himmelmann, K. Eid, P. Greminger, W. Vetter, and G. Schulthess
Tumor Necrosis Factor-{alpha} -308G>A Allelic Variant Modulates Iron Accumulation in Patients with Hereditary Hemochromatosis
Clin. Chem., August 1, 2006; 52(8): 1552 - 1558.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
H. M. Blanck, M. E Cogswell, C. Gillespie, and M. Reyes
Iron supplement use and iron status among US adults: results from the third National Health and Nutrition Examination Survey
Am. J. Clinical Nutrition, November 1, 2005; 82(5): 1024 - 1031.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
B. Schmitt, R. M. Golub, and R. Green
Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians
Ann Intern Med, October 4, 2005; 143(7): 522 - 536.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
J.K. Limdi and J.R. Crampton
Hereditary haemochromatosis
QJM, June 1, 2004; 97(6): 315 - 324.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. R. Hover, S. M. McDonnell, and W. Burke
Changing the Clinical Management of Hereditary Hemochromatosis: Translating Screening and Early Case Detection Strategies Into Clinical Practice
Arch Intern Med, May 10, 2004; 164(9): 957 - 961.
[Abstract] [Full Text] [PDF]


Home page
Ann Fam MedHome page
A. G. Mainous III, B. Wells, P. J. Carek, J. M. Gill, and M. E. Geesey
The Mortality Risk of Elevated Serum Transferrin Saturation and Consumption of Dietary Iron
Ann. Fam. Med, March 1, 2004; 2(2): 139 - 144.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
K. Premkumar and C. L. Bowlus
Ascorbic Acid Does Not Increase the Oxidative Stress Induced by Dietary Iron in C3H Mice
J. Nutr., February 1, 2004; 134(2): 435 - 438.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
F. J. Lloyd, V. F. Reyna, and P. Whalen
Accuracy and Ambiguity in Counseling Patients About Genetic Risk
Arch Intern Med, November 12, 2001; 161(20): 2411 - 2413.
[Full Text] [PDF]


Home page
JAMAHome page
A. M. Sanchez, G. B. Schreiber, J. Bethel, P. R. McCurdy, S. A. Glynn, A. E. Williams, R. Gilcher, and for the Retrovirus Epidemiology Donor Study
Prevalence, Donation Practices, and Risk Assessment of Blood Donors With Hemochromatosis
JAMA, September 26, 2001; 286(12): 1475 - 1481.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
E. H. Hanson, G. Imperatore, and W. Burke
HFE Gene and Hereditary Hemochromatosis: A HuGE Review
Am. J. Epidemiol., August 1, 2001; 154(3): 193 - 206.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. K. Steinberg, M. E. Cogswell, J. C. Chang, S. P. Caudill, G. M. McQuillan, B. A. Bowman, L. M. Grummer-Strawn, E. J. Sampson, M. J. Khoury, and M. L. Gallagher
Prevalence of C282Y and H63D Mutations in the Hemochromatosis (HFE) Gene in the United States
JAMA, May 2, 2001; 285(17): 2216 - 2222.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. M. Brittenham, H. G. Klein, J. P. Kushner, and R. S. Ajioka
Preserving the National Blood Supply
Hematology, January 1, 2001; 2001(1): 422 - 432.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
C. J Seamark, M. Hutchinson, I. Heath, and M F McMullin
Controversy in primary care: Should asymptomatic haemochromatosis be treated? Treatment can be onerous for patient and doctor Commentary: False certainty of clinical guidance Commentary: Early treatment is essential
BMJ, May 13, 2000; 320(7245): 1314 - 1317.
[Full Text]


Home page
ANN INTERN MEDHome page
H. B. El-Serag, J. M. Inadomi, and K. V. Kowdley
Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness Analysis
Ann Intern Med, February 15, 2000; 132(4): 261 - 269.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. M. Brittenham, G. Weiss, P. Brissot, F. Laine, A. Guillygomarc'h, D. Guyader, R. Moirand, and Y. Deugnier
Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism
Hematology, January 1, 2000; 2000(1): 39 - 50.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
N. C. Andrews
Disorders of Iron Metabolism
N. Engl. J. Med., December 23, 1999; 341(26): 1986 - 1995.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
V. Herbert
Hemochromatosis and Vitamin C
Ann Intern Med, September 21, 1999; 131(6): 475 - 476.
[Full Text] [PDF]


Home page
JAMAHome page
M. Levine, S. C. Rumsey, R. Daruwala, J. B. Park, and Y. Wang
Criteria and Recommendations for Vitamin C Intake
JAMA, April 21, 1999; 281(15): 1415 - 1423.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. E. Cogswell, S. M. McDonnell, M. J. Khoury, A. L. Franks, W. Burke, and G. Brittenham
Iron Overload, Public Health, and Genetics: Evaluating the Evidence for Hemochromatosis Screening
Ann Intern Med, December 1, 1998; 129(11_Part_2): 971 - 979.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. M. McDonnell, D. L. Witte, M. E. Cogswell, and R. McIntyre
Strategies To Increase Detection of Hemochromatosis
Ann Intern Med, December 1, 1998; 129(11_Part_2): 987 - 992.
[Abstract] [Full Text]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1998 by the American College of Physicians.